凯纷治疗原发性肝癌栓塞化疗术后疼痛的随机对照研究

Randomized controlled study on the curative effect of flurbiprofen in pain treatment after chemoembolization for hepatic neoplasms

目的:比较凯纷(氟比洛芬酯)与曲马多治疗原发性肝癌栓塞化疗后疼痛的临床疗效及不良反应。方法:对40例肝癌介入后疼痛患者,随机分为两组,分别于术后使用凯纷及曲马多进行治疗,凯纷剂量为50mg、曲马多剂量为50mg。治疗前后分别观察临床疗效、记录恶心、呕吐、便秘等不良反应,比较两组疗效与不良反应的发生率。结果:凯纷与曲马多的疼痛缓解率分别为85%与35%(χ2=12.665,P<0.05)及其不良反应发生率低,主要有恶心、呕吐等,未发现有明显严重不良反应,其中曲马多的恶心、呕吐发生率高于凯纷(χ2=17.857,P<0.05),其他不良反应的发生率两组无显著差异。结论:凯纷给药方式、疗效均优于曲马多,且副作用少,更适合用于肝癌栓塞化疗术后疼痛的治疗。

Objective：Comparison of flurbiprofen and tramadol in the treatment of hepatic neoplasms chemoembolization pain in clinical efficacy and adverse reaction.Methods：40 cases of the treatment of hepatic neoplasms chemoembolization pain were randomly divided into two groups,respectively,after the use of flurbiprofen and tramadol for treatment,flurbiprofen dose of 50 mg,tramadol dose of 50 mg.Clinical efficacy were observed before and after treatment,recording nausea,vomiting,constipation and other adverse reactions,compared the efficacy and the incidence of adverse reactions.Results：Flurbiprofen and tramadol pain relief rates were 85% and 35%（χ2=12.665,P0.05）,and its lower incidence of adverse reactions,mainly nausea,vomiting and found no significant serious adverse reactions.One of tramadol nausea and vomiting was higher than that flurbiprofen（χ2=17.857,P0.05）.The incidence of other adverse reactions was no significant difference between the two groups.Conclusion：Flurbiprofen delivery methods are superior efficacy of tramadol,and less side effects and is more suitable for hepatic neoplasms chemoembolization for the treatment of postoperative pain.